A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC

Sponsor
The First Affiliated Hospital of Guangzhou Medical University
Study ID
NCT06775275
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Resectable Lung Non-Small Cell Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Adebellizumab — DRUG
    adebrelimab
  • Bevacizumab — DRUG
    bevacizumab
  • Platinum-based chemotherapy — DRUG
    paclitaxel or albuminotaxol or docetaxel combined with platinum, pemetrexed combined with platinum. Platinums include carboplatin, cisplatin and nedaplatin.

Study Details

This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without bevacizumab for the treatment of resectable Stage II-IIIB (T3N2) NSQ-NSCLC and to explore biomarkers associated with efficacy.

Key Dates

First listed
Jan 15, 2025
Start date
Sep 24, 2024
Status verified
Jan 2025
Primary completion
Dec 31, 2025
Completion
Dec 31, 2029

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: four-drug combination group
    PD-L1 inhibitor with chemotherapy with Antiangiogenic therapy for neoadjuvant therapy
  • Experimental: three-drug combination group
    PD-L1 inhibitor with chemotherapy for neoadjuvant therapy

Primary Outcome Measure

Pathological complete response [ Time Frame: After 4 cycles of neoadjuvant therapy(3 weeks per cycle), surgical resection was performed at intervals of 4-6 weeks. Pathological response assessment results were assessed within one week after surgery. ]

Central Contacts

Related Studies